|Patents granted for Cleveland BioLabs' Protectan CBLB612|
|By Staff and Wire Reports|
|Monday, 04 October 2010 12:06|
Yet another positive development for Cleveland BioLabs, Inc.(NASDAQ:CBLI).
The Company announced today that it has received a notice of grant of patent for Protectan CBLB612 from South Africa and a notice of intent to grant patent for Protectan CBLB612 from the Eurasian Patent Organization (EAPO), which includes the Russian Federation and eight other member countries. These patents cover the various properties of Protectan CBLB612 and related compounds, including composition of matter and methods of use for protecting against apoptosis- a highly specific and tightly regulated form of cell death that can occur in response to external events such as exposure to radiation, toxic chemicals or internal stresses. Apoptosis is a major determinant of tissue damage caused by a variety of medical conditions including cerebral stroke, heart attack and acute renal failure. Conversely, apoptosis is also an important protective mechanism that allows the body to shed itself of defective cells, which otherwise can cause cancerous growth.
Yakov Kogan, Ph.D., MBA, Chief Operating Officer of Cleveland BioLabs, noted that these patents represent further validation of CBLB612's program and may facilitate future partnering discussions. "This is the first set of patent approvals for CBLB612. We have been progressing well with patent examination in various geographies and we hope to continue receiving grant notifications from different jurisdictions over the coming months."
Protectan CBLB612 is a proprietary synthetic agent that acts as a potent stimulator of hematopoietic stem cell proliferation and mobilization to peripheral blood, as demonstrated in both mice and non-human primates.
Short interest in CBLI is at an all time high since most shorters are playing the stock the same way they play most biotechs that pop on good news- as CBLI recenlty did when they announced a $45 million order from the U.S. Department of Defense.
Those shorts will be forced to cover the moment the company announces additional significant news and as reported by BioMedReports on Friday, that positive news catalyst may not be too far off in the horizon. Cleveland BioLabsis set for multiple streams of government orders and additional federal funding following their recent release of positive trial results.
Read the BioMedReports article here: http://biomedreports.com/investing/biotech-news/results-of-cleveland-biolabs-safety-study-will-impact-share-price.html
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites